within Pharmacolibrary.Drugs.ATC.A;

model A16AB20
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.078 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pegunigalsidase alfa is a recombinant human alpha-galactosidase enzyme produced in plant cells, indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare, genetic lysosomal storage disorder. The drug is approved in the EU and Israel, marketed under the name PRX-102.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with Fabry disease, both male and female, following intravenous infusion of 1 mg/kg.</p><h4>References</h4><ol><li><p>Schiffmann, R, et al., &amp; Hughes, D (2019). Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. <i>Journal of inherited metabolic disease</i> 42(3) 534â€“544. DOI:<a href=&quot;https://doi.org/10.1002/jimd.12080&quot;>10.1002/jimd.12080</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30834538/&quot;>https://pubmed.ncbi.nlm.nih.gov/30834538</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB20;
